Close Video

HZD.L229.00GBp-1.00 (-0.43%)

52wk Low / High
104.00 / 289.00
Market Cap
Shares in Issue
Earnings Per Share (TTM)
Current PE Ratio (TTM)
Div / Yield
- / -

Quotes delayed, except where indicated otherwise. Currency in GBp.


Horizon Discovery Group plc (LSE: HZD) (“Horizon”), is a world-leading gene editing company that designs and engineers genetically-modified cells and then applies them in research and clinical applications that advance human health.

Horizon’s core capabilities are built around its proprietary translational genomics platform, a highly precise and flexible suite of gene editing tools (rAAV, ZFN and CRISPR) able to alter almost any gene sequence in human or mammalian cell-lines.

Horizon offers over 23,000 catalogue products and related research services, almost all of which are based on the generation and application of cell and in vivo models that accurately recapitulate the disease-causing genetic anomalies found in diseases like cancer. Horizon’s commercial offering has been adopted by c1,400 unique research organisations in over 50 countries as well as in the Company’s own R&D pipeline to support a greater understanding of the genetic drivers of disease and the development of molecular, cell and gene therapies that can be prescribed on a personalised basis.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD”.


  • Dr Ian Gilham (Chair) -NE Chair Multiplicom NV & Biosurfit SA.
  • Dr Darrin Disley (CEO) – Raised c$200m business financing from grant, angel, corporate, vc & public market. Closed c$350m of product, service & licensing deals.
  • Richard Vellacott (CFO) – 15yrs as a chartered accountant.
  • NED’s – Dr Jonathan Milner, Mrs Susan Earle, Dr Susan Galbraith, Grahame Cook


Operating Profit / (Loss)(5,350)(10,290)
Profit / (Loss) before tax(6,073)(10,540)
Total assets65,68088,870
Cash & cash equivalents18,21525,067
Total liabilities7,1669,014
Net assets58,51479,856

Peer Group

  • Abcam (AIM: ABC): Life Science research
  • Bachem (SIX: BANB): Manufactures ingredients for pharmaceuticals, generic drugs & research supplies
  • Epistem Holdings (LSE: EPH): Stem cell treatment for oncology & gastrointestinal diseases
  • Sigma Aldrich (NASDAQ: SIAL): Develops broad rang of chemicals, biochecmicals & equipment
  • Qiagen (NASDAQ: QGEN): Provides samples & assy technologies

Major Shareholders


  • Dr J Milner – 10.31%
  • Dr D Disley – 0.73%
  • Mr Grahame Cook – 0.04%
  • Mrs Susane Searle – 0.05%
  • Dr Ian Gilham – 0.03%


  • Invesco – 12.11%
  • Telegraph Hill Partners – 11.18%
  • Henderson Global Investors – 10%
  • Legal & General – 7.23%
  • Aviva – 6.31%
  • Baillie Gifford – 5.15%
  • DFJ Esprit – 5.04%

Macro Indicators

“The new science of personalised medicine” (PWC report 2011).

Currently, the total US market for personalised medicine and healthcare (wide, by definition) is estimated at £149bn and is projected to surpass £288bn by 2015

The core diagnostic and therapeutic segment (pharmaceuticals, medical device and diagnostic companies) is estimated at £15bn, with an estimated annual growth rate of c.10%, to reach £27bn by 2015.

30% of all pharma companies now require research & development compounds to have a patient-relevant biomarker

Media coverage

Investor’s Chronicle (17 Apr 2015)
“Final Results out this week revealed that the Co had outperformed expectations, with full year revenues rising to £11.9m, 8% ahead of consensus estimates. BUY”

Mail on Sunday (23 Mar 2015)
“Discover the life science firm that will broaden your horizons.”

Shares (Dec 2014)
“15 for 2015: Horizon Discovery”

Broker Coverage

Panmure Gordon (House Broker)
“Horizon offers investors a rare opportunity to gain exposure to an enabling healthcare company operating a unique and enabling technology platform within its chosen markets.”

Submit your details to be kept up to date with announcements regarding Horizon Discovery Group Plc

We have a strict data protection policy and will not share your details with external parties.